Clinical trials: Odontogenic Cysts
Keratocystic Odontogenic Tumor
A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors
The purpose of this study is to determine how well a daily dose of 150 mg of Erivedge (vismodegib) reduces Keratocystic odontogenic tumor (KCOT) size, and to evaluate the safety of this dose.
- Trial name
- KCOT (NCT02366312)
- Testing
- vismodegib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- NYU College of Dentistry